ERS Genomics was formed to commercialise the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use.
CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods.
Our team has decades of experience in the field of genome editing and its application, in business development and licensing, licensing preclinical and clinical stage therapeutic products and drug delivery technologies, genome editing technologies as well as overseeing research and development.
To learn more about acquiring your license, contact us today.
Company Details
- Employees
- 10
- Founded
- 2014
- Address
- San Francisco, Ca 94102, Us
- Phone
- +353 1 539-0082
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- ersgenomics.com
- Keywords
- IP Licenses, CRISPR/Cas9, Intellectual Property, Biotechnology, Gene Editing, Life Science, Research, Pharmaceutical, Clinical Diagnostics, Synthetic Biology, Patents, Genetic Scissors, Genomics, CVC Portfolio, DNA Target, Guide RNAs.
- HQ
- San Francisco, CA
Ers Genomics Questions
Ers Genomics's helpline number is +353 1 539-0082
Ers Genomics's website is ersgenomics.com
Ers Genomics's LinkedIn profile is https://ie.linkedin.com/company/ers-genomics
Ers Genomics has
10 employees.
View email and phone details for 10
employees at Ers Genomics.
Ers Genomics's industry is
Biotechnology Research
Ers Genomics's top competitors are
Gsk,
Crispr Therapeutics,
Quanta Dialysis Technologies,
Genseq,
Medicines Discovery Catapult,
Nuritas,
Complete Genomics,
Econic Biosciences,
Xap Therapeutics,
Jumpcode Genomics.
Ers Genomics's support email address is info@ersgenomics.com
Ers Genomics's categories are Biotechnology Research
Ers Genomics's founding year is 2014
